Early treatment with prednisolone, but not acyclovir, promoted complete recovery of facial-nerve function in Bell palsy


Outcomes: Complete recovery (grade 1 on the House–Brackmann scale for facial-nerve function), health-related quality of life, facial appearance, and pain.

Patient follow-up: 90% (intention-to-treat analysis).

Main results
At 3 and 9 months, complete recovery rates were higher in the prednisolone groups than in the no-prednisolone groups but did not differ between the acyclovir groups and the no-acyclovir groups (Table). Compared with the group that received neither drug (complete recovery rates of 65% at 3 mo and 85% at 9 mo), complete recovery rates were increased in the group that received prednisolone alone but not in the groups that received acyclovir alone or both drugs. The addition of acyclovir to prednisolone did not increase the chance of complete recovery compared with prednisolone alone. At 3 months, health-related quality of life, facial appearance, and pain improved to a similar extent in all groups.

Conclusion
In patients with Bell palsy, early treatment with prednisolone, but not acyclovir, improved the chance of complete recovery of facial-nerve function.

Source of funding: Health Technology Assessment Program of the National Institute for Health Research.

For correspondence: Dr. F.M. Sullivan, University of Dundee, Dundee, Scotland, UK. E-mail f.m.sullivan@chs.dundee.ac.uk.

Clinical impact ratings: Emergency Med ★★★★★★ GIM/FP/GP ★★★★★★★ Neurology ★★★★★★★ Oncology ★★★★★★★★

Question
In patients with Bell palsy, does early treat-
ment with prednisolone or acyclovir improve the chance of complete recovery of facial-nerve function?

Methods
Design: 2 × 2 factorial, randomized, placebo-controlled trial.
Allocation: Concealed.*
Blinding: Blinded (clinicians, patients, data collectors, and outcome assessors).*
Follow-up period: Up to 9 months.
Setting: 17 hospitals in Scotland, United Kingdom.
Patients: 551 patients ≥ 16 years of age (mean age 44 y, 51% men) with unilateral facial-nerve weakness of no identifiable cause who were referred by their primary care physician or the emergency department within 72 hours of onset of symptoms. Exclusion criteria included pregnancy, uncontrolled diabetes, peptic ulcer disease, herpes zoster, and multiple sclerosis. 54% of patients started treatment within 24 hours of onset of symptoms. Mean score on the 6-grade House–Brackmann scale was 3.6 (higher grade indicates worse facial paralysis).

Intervention: Prednisolone, 25 mg twice daily, plus placebo for acyclovir (n = 138); acyclovir, 400 mg 5 times daily, plus placebo for prednisolone (n = 138); prednisolone plus acyclovir (n = 134); or both placebos (n = 141). Study drugs were taken for 10 days.

Commentary
Inflammatory, viral, and ischemic causes have been postulated for Bell palsy (1), and steroids and antiviral agents are commonly recommended. The most recent Cochrane reviews of these drugs for Bell palsy concluded that neither treatment has been proven to improve recovery (2, 3).

The study by Sullivan and colleagues is the first properly designed controlled trial of oral steroids for Bell palsy. Sullivan and colleagues showed that 10 days of prednisolone, 25 mg twice daily, is sufficient and not associated with antiviral treatment.

Early treatment with prednisolone or acyclovir for Bell palsy†

<table>
<thead>
<tr>
<th>Follow-up</th>
<th>Complete recovery rates‡</th>
<th>RBI (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisolone</td>
<td>No prednisolone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 mo</td>
<td>83%</td>
<td>64%</td>
<td>27% (15 to 37)</td>
</tr>
<tr>
<td>9 mo</td>
<td>94%</td>
<td>82%</td>
<td>15% (8 to 18)</td>
</tr>
<tr>
<td>Acyclovir</td>
<td>No acyclovir</td>
<td>RBR (CI)</td>
<td>NNH</td>
</tr>
<tr>
<td>3 mo</td>
<td>71%</td>
<td>76%</td>
<td>3.8% (−7 to 17)</td>
</tr>
<tr>
<td>9 mo</td>
<td>85%</td>
<td>91%</td>
<td>5.6% (−1 to 16)</td>
</tr>
</tbody>
</table>

†Abbreviations defined in Glossary. RBI, RBR, NNT, NNH, and CI calculated from odds ratios in article, adjusted for age, sex, baseline score, receipt of the other study drug, and time to start of treatment.

‡Grade 1 on the 6-category House–Brackmann scale for facial-nerve function.

References

Wieslaw Oczkowski, MD
McMaster University
Hamilton, Ontario, Canada